Executive‑Level Share Transactions at Kenvue Inc.: An Overview of Recent SEC Form 4 Filings
The U.S. Securities and Exchange Commission (SEC) received a series of Form 4 filings on 26 May 2026 that detail changes in the ownership of Kenvue Inc. shares by senior executives and directors. The filings, all covering the reporting period ending 21 May 2026, illustrate the continued use of deferred share unit (DSU) plans as a compensation mechanism within the company’s governance structure.
Key Transactions and Shareholding Adjustments
| Executive / Director | Nature of Transaction | Indirect Shares After Transaction | Additional DSU Shares |
|---|---|---|---|
| Jeffrey C. Smith (Director) | Acquisition of a substantial block via a Starboard‑managed account + grant of DSUs | >27 million shares | 25 000 |
| Sarah Hofstetter (Director) | Grant of DSUs | 10 300 (approx.) | – |
| Betsy Holden (Director) | Grant of DSUs | 10 300 (approx.) | – |
| Vasant Prabhu (Director) | Grant of DSUs | 10 300 (approx.) | – |
| Michael Sneed (Director) | Grant of DSUs | 10 300 (approx.) | – |
| Kathleen Pawlus (Director) | Grant of DSUs | 10 300 (approx.) | – |
| Leonardo Curado de Lemos Gomes (Director) | Exercise of DSUs (1 May 2026) | 24 000 | – |
All directors’ DSU grants were exercised at a conversion price of approximately $17.46 per share, corresponding to the market value of Kenvue shares at the time of conversion. Depending on the grant size, this exercise added between 16 000 and 25 000 shares to each director’s holdings. The DSU grants for the five directors in the second row of the table each comprised roughly 10 300 shares, with dividend‑equivalent adjustments adding a few additional shares where applicable.
Implications for Kenvue’s Capital Structure
Although these transactions represent significant individual share movements, they do not materially alter Kenvue’s overall ownership structure. The company’s deferred share unit plan remains a key tool for aligning executive incentives with shareholder value, a strategy common across many publicly traded firms in the pharmaceutical and consumer‑health sectors. By converting DSUs at a price tied to the current market, Kenvue ensures that compensation remains competitive while preserving long‑term ownership among its leadership.
Cross‑Industry Perspective
The use of DSU plans is not unique to the consumer‑health industry. Similar structures appear in technology, financial services, and industrial manufacturing, where companies seek to:
- Attract and retain talent in highly competitive markets.
- Align executive interests with long‑term shareholder returns.
- Manage dilution by deferring equity issuance until performance milestones are achieved.
In Kenvue’s case, the DSU plan functions within a broader framework of executive compensation that includes stock options, restricted stock units, and performance‑based awards. This multi‑layered approach reflects a mature corporate governance model that balances immediate reward with future value creation.
Economic Context
The timing of these filings coincides with a period of heightened volatility in U.S. equity markets, driven in part by macro‑economic uncertainties such as inflationary pressures, central‑bank policy shifts, and supply‑chain disruptions. Within this environment, Kenvue’s strategy of granting DSUs at a fixed conversion price offers a degree of predictability for both executives and shareholders. By locking in a conversion price close to the prevailing market rate, the company mitigates the risk of future share price depreciation affecting executive compensation payouts.
Moreover, the continued exercise of DSUs suggests confidence among senior leadership in the company’s future performance—a sentiment that can have a positive impact on investor perception and market valuation. In sectors where innovation cycles are long and capital intensity is high, such signals are particularly valuable.
Conclusion
The 26 May 2026 Form 4 filings from Kenvue Inc. provide a detailed snapshot of executive share ownership dynamics and illustrate the continued reliance on deferred share units as a compensation tool. While the transactions do not significantly shift the company’s ownership landscape, they underscore the importance of sophisticated equity plans in modern corporate governance. As Kenvue navigates the current economic landscape, these mechanisms will likely continue to play a pivotal role in aligning executive incentives with shareholder interests across the broader consumer‑health industry and beyond.
